We celebrate Mitchell Steele, vice president on the Satori private equity team, on his five-year anniversary with the firm! As a member of the private equity team, Mitch – shown below after his team took first place in the firm's friendly axe-throwing competition – collaborates with Satori's portfolio companies and analyzes potential investment opportunities.?Mitch's team members value him for his sound judgment, learner mindset, and can-do spirit, noting that he is the first to volunteer for a task or project, often articulates a clear opinion that generates constructive dialogue for the team, and always brings his authentic self to his work.?Mitch is a leader, an admired colleague, and a trusted representative of Satori. Thank you, Mitch, for five extraordinary years.?We look forward to many more!
Satori Capital
投资管理
Dallas，TX 6,342 位关注者
We exist to create, fund, and inspire businesses that elevate humanity.
关于我们
Satori Capital is a Texas-based multi-strategy investment firm founded upon the principles of conscious capitalism. Satori’s private equity business partners with leadership teams of companies with $5 million to $25 million of EBITDA that operate with a long-term perspective, commit to their mission or purpose, and create value for all stakeholders. Satori's alternatives investment platform, Satori Alpha,?creates and manages customized portfolios?designed to meet the unique objectives of institutions, family offices, and sophisticated private investors. For additional information, please visit?www.satoricapital.com.
- 网站
-
https://www.satoricapital.com
Satori Capital的外部链接
- 所属行业
- 投资管理
- 规模
- 11-50 人
- 总部
- Dallas，TX
- 类型
- 私人持股
- 创立
- 2008
地点
-
主要
获取路线
2501 N Harwood St
US，TX，Dallas，75201
Satori Capital员工
动态
-
We are thrilled to be ranked #1 on the 'Best Companies to Work for in Fort Worth' list – for a fifth time! #BestCompanies #Culture
Satori Capital Ranked #1 for the Fifth Time in Fort Worth ‘Best Companies’ Awards
https://www.satoricapital.com
-
We are hiring! Satori Capital is seeking an office manager and receptionist, or as we like to call it, a "Director of First Impressions," who will manage the daily operations of our Dallas office to ensure a welcoming, efficient, and professional work environment.?See the job description below if you or someone you know might be the right fit. #hiring #recruiting
Satori Capital - Dallas Office Manager / Receptionist
jobs.lever.co
-
The inaugural issue of 'New in Human Flourishing' is out today! Find Satori Neuro's perspectives on industry trends, breaking neuro news, and Amy Kruse's travels.
New in Human Flourishing
satorineuro.substack.com
-
We are pleased to announce our investment in Automatic Fire Protection, LLC ("AFP"), a fully integrated provider of fire sprinkler and alarm systems.
Satori Capital Invests in Automatic Fire Protection, LLC
businesswire.com
-
We are hiring! Satori Capital is seeking an office manager and receptionist, or as we like to call it, a "Director of First Impressions," who will manage the daily operations of our Dallas office to ensure a welcoming, efficient, and professional work environment.? See the job description below if you or someone you know might be the right fit. #hiring #recruiting
Satori Capital - Dallas Office Manager / Receptionist
jobs.lever.co
-
We thank the team at Able Machinery Movers for embracing the principles of conscious capitalism during our stewardship of the company.
Satori Capital - Conscious Capitalism in Action at Able
https://www.youtube.com/
-
Congratulations Sam Clark, MD PhD, Dustin Tetzl, MD, and to the whole Terran Biosciences team for the news on TerXT!
Today, we’re excited to announce the development of TerXT, a combination of novel prodrugs of xanomeline and trospium designed to be long-acting treatments for schizophrenia. Using a novel prodrug approach we’ve been able to overcome inherent pharmacokinetic and physical property limitations of xanomeline and trospium with the goal of creating fixed-dose combinations for daily oral administration as well as long-acting intramuscular injection with multi-month duration. The original combination of xanomeline and trospium has been shown in recent trials to be an effective therapeutic for schizophrenia and is currently undergoing FDA review via the 505(b)(1) pathway. If approved, Terran plans to use the rapid 505(b)(2) approval pathway for our next-generation prodrug forms, potentially enabling market entry approximately five years after the initial xanomeline/trospium approval. This milestone is the result of tireless efforts by over 200 chemists who designed and synthesized 500 prodrugs, which were then tested in 285 in vitro and 365 in vivo studies to select the lead prodrug forms with optimized properties for long-acting administration. Terran has also now received notice of patent claims found to be allowable from the United States Patent and Trademark Office for the composition of matter for the world’s first prodrugs of xanomeline. The development of TerXT represents a major step in Terran’s mission to create effective, accessible, affordable, and patient-friendly neuropsychiatric therapies through innovative drug design and regulatory strategies. Read the press release here: https://bit.ly/4dI3OQy #schizophrenia #mentalhealth #drugdevelopment
Terran Biosciences announces development of TerXT, a combination of xanomeline and trospium prodrugs for the treatment of schizophrenia, and intends to pursue accelerated 505(b)(2) approval pathway
-
Satori Neuro CIO Dr. Amy Kruse recently served as neurotechnology track chair at the SynBioBeta 2024 conference in San Jose.?Here she is moderating the panel "Energizing the Brain: Emerging Technologies in Neurostimulation." The panel featured (left to right): - Openwater founder Mary Lou Jepsen, whose open-source focused ultrasound technologies are lowering the barriers to neuro research - Motif Neurotech CEO Jacob Robinson, whose team has developed a tiny brain stimulator implant that never touches the brain (see lower photo for 3-D printed scale replica) - Ampa CEO Don Vaughn, Ph.D., who is making inroads to scalability for transcranial magnetic stimulation
-